In particular, while factor IX (FIX) gene therapy using adeno-associated or lentiviral (LV) vectors in vivo is a promising treatment option for hemophilia B (9, 10), humoral and cell-mediated immune responses triggered by the transgene may result in lack of therapeutic efficacy (11, 12). The gene discussed is F9; the disease is hemophilia B.